Orchid Pharma net up 8%
BS 200 Scorecard
| The turnover of the company grew marginally to Rs 245.73 crore from Rs 239.31 crore during the period under review. For the half year ended September 30, net profit of the company grew by 27.46 per cent to Rs 44.04 crore as against Rs 34.55 crore in the same period last fiscal. |
| Turnover of the company was Rs 447.44 crore, a growth of 9.2 per cent over Rs 409.57 crore during the last year.On a consolidated basis, the company's net profit grew by 71 per cent to Rs 35.24 crore for the half year ended September 30 compared to Rs 20.60 crore in the same period last year. |
| Turnover of the company was Rs 472.83 crore, higher by about 8 per cent compared with Rs 439.54 crore in the previous year. |
| K Raghavendra Rao, managing director, Orchid Chemicals and Pharmaceuticals Ltd, said the second quarter has been a satisfying one on key strategic fronts, as the company received 3 USFDA approvals for its ANDAs during the quarter and in October, taking the total ANDA approval count to 18. |
| "Our API and formulations Sterile Cephalosporin facilities were approved by the UK-MHRA (Medicines and Healthcare Products Regulatory Agency). This would be a major enabler for our broader entry into the large EU generics space. With more product introductions slated in the ensuing quarters based on progressive approvals, we are confident of achieving a strong performance during the further quarters also," he added. |